CN118829430A - 治疗前列腺癌的方法 - Google Patents

治疗前列腺癌的方法 Download PDF

Info

Publication number
CN118829430A
CN118829430A CN202380021612.6A CN202380021612A CN118829430A CN 118829430 A CN118829430 A CN 118829430A CN 202380021612 A CN202380021612 A CN 202380021612A CN 118829430 A CN118829430 A CN 118829430A
Authority
CN
China
Prior art keywords
olaparib
months
subject
use according
abiraterone acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380021612.6A
Other languages
English (en)
Chinese (zh)
Inventor
康金玉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN118829430A publication Critical patent/CN118829430A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202380021612.6A 2022-02-15 2023-02-14 治疗前列腺癌的方法 Pending CN118829430A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263268026P 2022-02-15 2022-02-15
US63/268026 2022-02-15
PCT/EP2023/053555 WO2023156357A1 (en) 2022-02-15 2023-02-14 Methods of treating prostate cancer

Publications (1)

Publication Number Publication Date
CN118829430A true CN118829430A (zh) 2024-10-22

Family

ID=85283519

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380021612.6A Pending CN118829430A (zh) 2022-02-15 2023-02-14 治疗前列腺癌的方法

Country Status (11)

Country Link
US (1) US20250134887A1 (https=)
EP (1) EP4479053A1 (https=)
JP (1) JP2025505041A (https=)
KR (1) KR20240148418A (https=)
CN (1) CN118829430A (https=)
AU (1) AU2023220646A1 (https=)
CA (1) CA3250763A1 (https=)
IL (1) IL314798A (https=)
MX (1) MX2024009923A (https=)
TW (1) TW202400267A (https=)
WO (1) WO2023156357A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
US12280049B2 (en) * 2020-08-04 2025-04-22 Astrazeneca Ab Methods of delaying pain progression and treating prostate cancer

Also Published As

Publication number Publication date
US20250134887A1 (en) 2025-05-01
EP4479053A1 (en) 2024-12-25
WO2023156357A1 (en) 2023-08-24
TW202400267A (zh) 2024-01-01
KR20240148418A (ko) 2024-10-11
MX2024009923A (es) 2024-08-22
JP2025505041A (ja) 2025-02-19
IL314798A (en) 2024-10-01
CA3250763A1 (en) 2023-08-24
AU2023220646A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
Clarke et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer
JP7738612B2 (ja) 類上皮細胞腫瘍を処置する方法
JP7407880B2 (ja) 前立腺癌の併用療法
Mulders et al. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy
KR102191311B1 (ko) 폐암의 치료 방법
de Kouchkovsky et al. Diagnosis and management of neuroendocrine prostate cancer
Wei et al. Efficacy, tolerability, and pharmacokinetics of combined targeted MEK and dual mTORC1/2 inhibition in a preclinical model of mucosal melanoma
Spreafico et al. A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients
BR112021014657A2 (pt) Métodos para tratar câncer de próstata com base em subtipos moleculares
US20250235451A1 (en) Methods of Delaying Pain Progression And Treating Prostate Cancer
CN118829430A (zh) 治疗前列腺癌的方法
Sunkara et al. Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors in pancreatic cancer
Ławnicka Current prospects for adrenocortical carcinoma pharmacotherapy
JP2025508399A (ja) 脳がんの処置のためのニラパリブの使用
JP2024516441A (ja) ソトラシブ製剤
Szczotka et al. Role of PARP inhibitors in prostate cancer
US20250275978A1 (en) Use of onvansertib as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer
Heidenreich et al. Modern management of castration-resistant prostate cancer
Mountzios et al. Impact of bevacizumab versus erlotinib on tumor metrics in patients with previously untreated advanced non-small cell lung cancer: a study by the hellenic cooperative oncology group
Lange et al. First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer
WO2026096660A1 (en) Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
Ma et al. The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
WO2025188679A1 (en) Use of plk1 inhibitor and paclitaxel in treating small cell lung cancer
WO2025117928A1 (en) Breast cancer treatment using pi3k inhibitor and cell cycle inhibitor
RU2808427C2 (ru) Способы лечения рака поджелудочной железы с применением комбинированной терапии, включающей липосомальный иринотекан

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination